Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

New therapeutic strategies for malignant mesothelioma are urgently needed. In the DETERMINE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody tremelimumab in patients with previously treated advanced malignant mesothelioma.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet Oncology 2017-09, Vol.18 (9), p.1261-1273
Hauptverfasser: Maio, Michele, Scherpereel, Arnaud, Calabrò, Luana, Aerts, Joachim, Perez, Susana Cedres, Bearz, Alessandra, Nackaerts, Kristiaan, Fennell, Dean A, Kowalski, Dariusz, Tsao, Anne S, Taylor, Paul, Grosso, Federica, Antonia, Scott J, Nowak, Anna K, Taboada, Maria, Puglisi, Martina, Stockman, Paul K, Kindler, Hedy L
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:New therapeutic strategies for malignant mesothelioma are urgently needed. In the DETERMINE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody tremelimumab in patients with previously treated advanced malignant mesothelioma.
ISSN:1470-2045